26.03 -0.31 (-1.18%) | 02-06 11:02 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 31.6 | 1-year : | 33.89 |
Resists | First : | 27.05 | Second : | 29.02 |
Pivot price | 26.4 ![]() |
|||
Supports | First : | 23.87 | Second : | 19.86 |
MAs | MA(5) : | 25.96 ![]() |
MA(20) : | 26.36 ![]() |
MA(100) : | 28.32 ![]() |
MA(250) : | 26.58 ![]() |
|
MACD | MACD : | -0.4 ![]() |
Signal : | -0.4 ![]() |
%K %D | K(14,3) : | 31.5 ![]() |
D(3) : | 29.2 ![]() |
RSI | RSI(14): 47.9 ![]() |
|||
52-week | High : | 35 | Low : | 19.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ XOMA ] has closed above bottom band by 45.4%. Bollinger Bands are 44.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 26.37 - 26.48 | 26.48 - 26.58 |
Low: | 25.27 - 25.38 | 25.38 - 25.5 |
Close: | 26.15 - 26.34 | 26.34 - 26.51 |
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Wed, 05 Feb 2025
XOMA stock price target cut to $104 by H.C. Wainwright - MSN
Tue, 04 Feb 2025
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Tue, 04 Feb 2025
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Eagle-Tribune
Tue, 04 Feb 2025
Exclusive Healthcare Insights: XOMA Leadership Takes Center Stage at Oppenheimer Conference - StockTitan
Mon, 03 Feb 2025
Forecasting The Future: 5 Analyst Projections For XOMA Royalty - Benzinga
Sat, 01 Feb 2025
XOMA Co. (NASDAQ:XOMA) Major Shareholder Sells $13,069,366.20 in Stock - MarketBeat
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 12 (M) |
Shares Float | 8 (M) |
Held by Insiders | 0.8 (%) |
Held by Institutions | 59.7 (%) |
Shares Short | 174 (K) |
Shares Short P.Month | 139 (K) |
EPS | -3.07 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 7.21 |
Profit Margin | -138.7 % |
Operating Margin | -22.8 % |
Return on Assets (ttm) | -5.6 % |
Return on Equity (ttm) | -31.5 % |
Qtrly Rev. Growth | 767 % |
Gross Profit (p.s.) | 1.66 |
Sales Per Share | 1.83 |
EBITDA (p.s.) | -1.29 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -15 (M) |
Levered Free Cash Flow | -19 (M) |
PE Ratio | -8.57 |
PEG Ratio | 0 |
Price to Book value | 3.64 |
Price to Sales | 14.33 |
Price to Cash Flow | -20.98 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |